---
title: "Senores Pharmaceuticals Ltd (SENORES) — Share Price, Financials & Analysis"
symbol: "SENORES"
company: "Senores Pharmaceuticals Ltd"
canonical: "https://tapetide.com/stocks/SENORES"
isin: "INE0RB801010"
nse_symbol: "SENORES"
bse_code: "544319"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
market_cap_cr: 6659.81
generated_at: "2026-09-13T18:57:52.191Z"
---

# Senores Pharmaceuticals Ltd (SENORES)

Canonical page: https://tapetide.com/stocks/SENORES

## Company

- **NSE Symbol:** SENORES
- **BSE Code:** 544319
- **ISIN:** INE0RB801010
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2024-12-30
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** senorespharma.com

## About

Incorporated in 2015, Senores Pharmaceuticals Ltd manufactures and develops affordable and high-quality complex generics certified by global food and drugs authorities[1]

## Latest Price

- **Price:** ₹1467.3
- **Change:** +4.2 (+0.29%)
- **Open:** ₹1452
- **Day High:** ₹1480
- **Day Low:** ₹1437.1
- **Previous Close:** ₹1463.1
- **Volume:** 134825
- **As Of:** 2026-09-11T10:27:20+00:00

## Key Fundamentals

Observed at 2026-09-11T04:46:45.768236Z.

- **Market Cap:** ₹6659.81 Cr
- **Classification:** Microcap
- **P/E (reported):** 51.5
- **P/E (TTM):** 53.49
- **EPS (TTM):** ₹27.43
- **Book Value:** ₹202.72
- **Price to Book:** 7.21
- **Dividend Yield:** 0%
- **ROE:** 7.18%
- **ROCE:** 9.34%
- **Debt to Equity:** 0.37
- **Revenue (yearly):** ₹632.63 Cr
- **Net Income:** ₹139.16 Cr
- **EBITDA:** ₹168.32 Cr
- **52-Week High:** ₹1599
- **52-Week Low:** ₹662.45
- **RSI (14):** 51.22

## Tapetide Score

- **Score:** 54 / 100
- **Score date:** 2026-09-04
- **Archetype:** Trend Ahead of Fundamentals
- **What it means:** The price trend is running ahead of what the financials currently support. Moves like this depend on the fundamentals catching up; check what would have to be true for that.
- **Pillar profile:** Quality: Weak · Valuation: Expensive · Momentum: Rising
- **Percentile:** 65.6 (of 4473 scored stocks)
- **Confidence:** 98%
- **Data coverage:** 95%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 32.18 | 9% |
| growth | 97.04 | 9% |
| momentum | 90.61 | 12% |
| ownership | 69.95 | 24% |
| quality | 38.28 | 22% |
| valuation | 26.04 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company is expected to give good quarter

### Weaknesses

- Stock is trading at 7.24 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 13.9% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 187 days.
- Working capital days have increased from 67.9 days to 132 days

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | -78.68% | — | -444.74% |
| ebitda margin growth | -13.19% | -5.13% | 21.19% | 50.15% |
| net income growth | -16.89% | 138.7% | 139% | — |
| revenue growth | -5.13% | 51.53% | 162% | 112.5% |
| roce | -16.52% | 1.63% | -49.27% | 10.1% |
| roe | -16.96% | -49.15% | 13.28% | -61.25% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 79 | 102 | 80 | 101 | 103 | 114 | 138 | 162 | 171 | 175 | 180 |
| Expenses | 64 | 80 | 59 | 77 | 77 | 95 | 104 | 112 | 121 | 128 | 126 |
| Operating Profit | 15 | 22 | 21 | 23 | 26 | 19 | 34 | 50 | 50 | 47 | 54 |
| OPM % | 19 | 22 | 27 | 23 | 25 | 17 | 25 | 31 | 29 | 27 | 30 |
| Other Income | 1 | 2 | 0 | 2 | 5 | 12 | 3 | 5 | 7 | 18 | 3 |
| Interest | 2 | 3 | 5 | 5 | 6 | 5 | 5 | 6 | 5 | 8 | 7 |
| Depreciation | 3 | 4 | 4 | 4 | 4 | 5 | 6 | 8 | 8 | 9 | 10 |
| Profit before tax | 10 | 18 | 13 | 16 | 20 | 21 | 26 | 41 | 45 | 47 | 39 |
| Tax % | 31 | 19 | 19 | 18 | 20 | 13 | 20 | 26 | 25 | 23 | 23 |
| Net Profit | 7 | 14 | 11 | 13 | 16 | 18 | 21 | 30 | 34 | 37 | 30 |
| EPS in Rs | 2.37 | 5.23 | 3.23 | 3.86 | 3.73 | 3.87 | 4.28 | 7.03 | 6.87 | 6.86 | 6.67 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- |
| Sales | 14 | 35 | 215 | 398 | 633 | 688 |
| Expenses | 12 | 23 | 173 | 309 | 464 | 487 |
| Operating Profit | 2 | 13 | 42 | 90 | 168 | 201 |
| OPM % | 14 | 36 | 19 | 23 | 27 | 29 |
| Other Income | 0 | 4 | 3 | 19 | 47 | 33 |
| Interest | 1 | 2 | 9 | 22 | 25 | 27 |
| Depreciation | 1 | 2 | 10 | 17 | 31 | 35 |
| Profit before tax | 1 | 12 | 25 | 71 | 159 | 172 |
| Tax % | 13 | 32 | -31 | 17 | 24 | — |
| Net Profit | 1 | 8 | 33 | 58 | 122 | 131 |
| EPS in Rs | 1.01 | 8.59 | 10.31 | 12.72 | 25.05 | 27.43 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Equity Capital | 9 | 10 | 31 | 46 | 46 |
| Reserves | 28 | 36 | 174 | 740 | 888 |
| Borrowings | 15 | 63 | 258 | 315 | 342 |
| Other Liabilities | 8 | 23 | 160 | 126 | 328 |
| Total Liabilities | 59 | 131 | 622 | 1227 | 1604 |
| Fixed Assets | 7 | 27 | 235 | 301 | 755 |
| CWIP | 8 | 34 | 97 | 172 | 17 |
| Investments | 15 | 16 | 0 | 0 | 4 |
| Other Assets | 29 | 53 | 289 | 754 | 827 |
| Total Assets | 59 | 131 | 622 | 1227 | 1604 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | -10 | -1 | -26 | -46 | 62 |
| Cash from Investing Activity | -24 | -48 | -54 | -429 | -121 |
| Cash from Financing Activity | 36 | 46 | 87 | 573 | -1 |
| Net Cash Flow | 2 | -3 | 8 | 98 | -60 |
| Free Cash Flow | -21 | -48 | -78 | -203 | -203 |
| CFO/OP | -526 | 3 | -56 | -41 | 45 |

### Ratios

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Debtor Days | 506 | 228 | 191 | 114 | 187 |
| Inventory Days | 135 | 89 | 184 | 232 | 130 |
| Days Payable | 324 | 388 | 556 | 275 | 340 |
| Cash Conversion Cycle | 317 | -71 | -182 | 70 | -24 |
| Working Capital Days | 359 | -7 | -16 | 88 | 132 |
| ROCE % | — | 18 | 12 | 11 | 15 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 45.76% | 45.76% | 45.77% | 45.78% | 45.8% | 45.8% | 45.82% | 45.82% |
| FIIs | 5.51% | 4.25% | 4.17% | 3.67% | 4.28% | 3.35% | 3.64% | 6.62% |
| DIIs | 18.61% | 11.78% | 9.65% | 9.51% | 8.61% | 9.31% | 9.61% | 9.77% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 27.88% | 28.71% | 31.43% | 31.44% | 31.09% | 31.94% | 31.64% | 29.25% |
| Others | 2.23% | 9.49% | 8.97% | 9.6% | 10.22% | 9.59% | 9.3% | 8.55% |
| No. of Shareholders | 43707 | 43707 | 37653 | 36389 | 34917 | 34401 | 34126 | 36498 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Buy
- **Buy / Neutral / Sell:** 8 / 7 / 4

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 1462.21 | Buy |
| EMA (10) | 1471.93 | Sell |
| SMA (20) | 1486.52 | Sell |
| EMA (20) | 1465.93 | Buy |
| SMA (50) | 1432.3 | Buy |
| EMA (50) | 1407.42 | Buy |
| SMA (100) | 1265.77 | Buy |
| EMA (100) | 1282.98 | Buy |
| SMA (200) | 1031.32 | Buy |
| EMA (200) | 1102.02 | Buy |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 51.88 | Neutral |
| MACD (12,26,9) | 13.44 | Sell |
| Stochastic (14,3,3) | 38.73 | Neutral |
| ADX (14) | 18.55 | Neutral |
| Williams %R (14) | -53.21 | Neutral |
| ATR (14) | 54.61 | High Volatility |
| ROC (12) | -1.83 | Sell |
| Stoch RSI (14) | 39.11 | Neutral |
| UO (7,14,28) | 47.61 | Neutral |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 4 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |

Based on 4 analyst ratings, observed at 2026-09-11T04:46:48.035659+00:00.

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 9 Mar - Analyst/Institutional investor group meeting on 12 Mar 2026, Ahmedabad; physical, public information only. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 9 Mar - Analyst/Institutional investor group meeting on 12 Mar 2026, Ahmedabad; physical, public information only.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b87b2fb6-6b7e-49eb-a3e1-28623f899167.pdf) |
| 8 May - Senores Pharmaceuticals will hold Q4FY26 earnings call on May 14, 2026 at 5:00 P.M. IST. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 8 May - Senores Pharmaceuticals will hold Q4FY26 earnings call on May 14, 2026 at 5:00 P.M. IST.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/73512d6b-dc96-4629-bbdb-a1075d67820d.pdf) |
| 8 May - Board meeting on May 14, 2026 to approve FY26 audited standalone and consolidated results. | [Board Meeting Intimation for Considering And Approving The Audited Consolidated And Standalone Financial Results Of The Company For The Quarter And Financial Year Ended March 31, 2026 And To Transact Other Business Matters 8 May - Board meeting on May 14, 2026 to approve FY26 audited standalone and consolidated results.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/8768c84e-b3bd-4c04-9afb-39ae8aeafcb6.pdf) |
| 6 Apr - Senores Pharmaceuticals Limited has informed regarding Certificate pursuant to Regulation 74(5) of SEBI (DP)Regulations,2018 for quarter ended March 31, 2026 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 Apr - Senores Pharmaceuticals Limited has informed regarding Certificate pursuant to Regulation 74(5) of SEBI (DP)Regulations,2018 for quarter ended March 31, 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/02d63fe9-52e1-4d69-bc0f-76464f7c2cb5.pdf) |
| 3 Mar - Issued corporate guarantee up to USD 4,100,000 for US subsidiary's HDFC Bank credit facilities on March 3, 2026. | [Announcement Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 3 Mar - Issued corporate guarantee up to USD 4,100,000 for US subsidiary's HDFC Bank credit facilities on March 3, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1741f873-ec1a-4a94-8a15-90fd179f3363.pdf) |
| 3 Mar - Corporate guarantee up to USD1,500,000 to HDFC Bank for Havix (Aavis), dated March 3, 2026; max 10-year. | [Announcement Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 3 Mar - Corporate guarantee up to USD1,500,000 to HDFC Bank for Havix (Aavis), dated March 3, 2026; max 10-year.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e8a6d0e5-e4f6-4cac-9b89-a2f3f5ea19ad.pdf) |
| 3 Apr - SPI formed Amerisyn, LLC in North Carolina with 70% membership interest on April 2, 2026. | [Announcement under Regulation 30 (LODR)-Acquisition 3 Apr - SPI formed Amerisyn, LLC in North Carolina with 70% membership interest on April 2, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5e345e70-8d3c-4450-ae46-235c1bb8f25c.pdf) |
| 3 Apr - Senores subsidiary SPI formed JV Amerisyn, LLC on April 2, 2026 for U.S. federal and defense supplies. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 3 Apr - Senores subsidiary SPI formed JV Amerisyn, LLC on April 2, 2026 for U.S. federal and defense supplies.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e18aec31-743f-4729-9d40-3bef5f38cde7.pdf) |
| 29 Apr - Senores Pharmaceuticals confirms it is not a Large Corporate; outstanding borrowing was Rs 54.07 crore as of March 31, 2025. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 29 Apr - Senores Pharmaceuticals confirms it is not a Large Corporate; outstanding borrowing was Rs 54.07 crore as of March 31, 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a612cd31-8ab9-4b0c-ae4c-0e4899118231.pdf) |
| 29 Apr - Senores Pharmaceuticals confirms it is not a Large Corporate; outstanding borrowing was Rs 54.07 crore as of March 31, 2025. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 29 Apr - Senores Pharmaceuticals confirms it is not a Large Corporate; outstanding borrowing was Rs 54.07 crore as of March 31, 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/a612cd31-8ab9-4b0c-ae4c-0e4899118231.pdf) |

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-09 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1b2b200f-bd8c-4328-810b-e2a63516c960.pdf) |
| 2026-09-04 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3cc82321-8604-4eae-88e6-1fb78c17470f.pdf) |
| 2026-09-03 | [Shareholder Meeting To Be Held On September 25 2026 At 11:30 Am (IST)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0d40beeb-263c-4838-810c-a39b6df600ff.pdf) |
| 2026-09-03 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d3819220-5329-4497-8643-9124feb9e770.pdf) |
| 2026-09-03 | [Business Responsibility and Sustainability Reporting (BRSR)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=94d0499f-47c7-42b0-9b5f-4039ec81929f.pdf) |
| 2026-08-27 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bc27d1e8-c22d-4dbd-83dd-71951b70f6f4.pdf) |
| 2026-08-27 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c4ac981f-3720-41fa-8668-24f5beaf2608.pdf) |
| 2026-08-26 | [Board Meeting Outcome for Senores Pharmaceuticals Limited Has Informed The Exchange Regarding Outcome Of Board Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cfde7484-bfc4-47d7-ac58-2517296f4894.pdf) |
| 2026-08-26 | [Announcement under Regulation 30 (LODR)-Acquisition](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=194d0444-51be-415b-8353-1a65de61a851.pdf) |
| 2026-08-26 | [Announcement under Regulation 30 (LODR)-Acquisition](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=30732120-f1d3-43c0-9a4e-c5babb60b601.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-08-03 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6f0da5d0-685b-4dd0-b80d-d18f8aa7a74c.pdf) |
| 2026-05-19 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=33171e88-ed30-44a9-84e4-c650993e0bf5.pdf) |
| 2026-01-27 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fb349c3f-3a5a-4bfc-b22b-b952b3cda929.pdf) |
| 2025-11-13 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1d6b5c6b-9d5b-417e-ac82-3aec59682705.pdf) |
| 2025-07-30 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c1ad0fa0-3887-47a6-a7ec-cd78979980ab.pdf) |
| 2025-05-22 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3da94862-93c4-4ac7-9508-a7e51a4203b1.pdf) |
| 2025-01-30 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4cf3f9dc-057c-43d5-8211-433755b6b5e1.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-07-27 | [Financial Results For Quarter Ended June 30 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=164a21ae-c7f6-44d0-8896-6686cdf0e693.pdf) |
| 2026-05-14 | [Financial Results For Quarter And Financial Year Ended March 31 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=579912a3-e1de-404e-b703-7a17b8b973e6.pdf) |
| 2026-01-20 | [Results For Quarter And Nine Months Ended December 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a4eaecfe-32ba-4b3a-97fd-91c220de08af.pdf) |
| 2025-11-06 | [Results For Quarter And Half Year Ended September 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=54268f95-c854-4a67-a638-034be381c495.pdf) |
| 2025-07-23 | [Financial Results For Quarter Ended On June 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c48bc9ab-ce84-42b4-be3c-978c934d0737.pdf) |
| 2025-05-16 | [Audited Standalone And Consolidated Financial Results For Quarter And Financial Year Ended March 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4ce7feff-eec5-4252-8dad-385809367244.pdf) |
| 2025-01-23 | [Results For Quarter And Nine Months Ended December 31 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=338ae28d-3377-47fc-987c-ec57a05678ae.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-07-27 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=905eda76-56fe-4da9-baeb-efee22167225.pdf) |
| 2026-05-14 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f5b13496-8d69-4e68-8902-c94f8fffd4e3.pdf) |
| 2026-01-20 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1e0dcb04-9670-4851-a381-cf5c0a5d34fd.pdf) |
| 2025-12-15 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6a2c9f77-55fb-4efe-b3f1-530983767dc2.pdf) |
| 2025-11-06 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ce4efec9-6bad-4249-90d2-721dcdb9caae.pdf) |
| 2025-07-23 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ac708ea4-5002-47b3-9d76-4bc491661e1f.pdf) |
| 2025-05-16 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=46eafcf0-b828-46cb-975a-3c3bf038e3d2.pdf) |
| 2025-05-16 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=673ded1e-4680-446d-8ae0-b9609a20598e.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-07-27 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fc65bd15-2fb4-400f-989b-480ae838c0bc.pdf) |
| 2026-05-14 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=27292f6f-fec8-42e2-9805-353c788dd17c.pdf) |
| 2026-01-20 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=149d8c3c-c868-4c2b-9756-b4a008c7bb71.pdf) |
| 2025-12-16 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4fccbd3c-3ef3-49ca-bca7-acd092f7d6dd.pdf) |
| 2025-11-06 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6eb9728d-bb3a-4488-90c6-1ce5f0653697.pdf) |
| 2025-07-24 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=715b10a1-8445-4ccc-ba7e-502a738afbad.pdf) |
| 2025-05-16 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=43e6850e-86ab-4f1f-84f5-71d8306ef077.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1d6b5c6b-9d5b-417e-ac82-3aec59682705.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/33171e88-ed30-44a9-84e4-c650993e0bf5.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/33171e88-ed30-44a9-84e4-c650993e0bf5.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f5b13496-8d69-4e68-8902-c94f8fffd4e3.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/f5b13496-8d69-4e68-8902-c94f8fffd4e3.pdf) |
| May 2025 | [Concall - May 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/46eafcf0-b828-46cb-975a-3c3bf038e3d2.pdf) |
| May 2025 | [Concall - May 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3da94862-93c4-4ac7-9508-a7e51a4203b1.pdf) |
| Jul 2025 | [Concall - Jul 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c1ad0fa0-3887-47a6-a7ec-cd78979980ab.pdf) |
| Jan 2026 | [Concall - Jan 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/fb349c3f-3a5a-4bfc-b22b-b952b3cda929.pdf) |
| Jan 2025 | [Concall - Jan 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4cf3f9dc-057c-43d5-8211-433755b6b5e1.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2e6620e4-47a1-40a8-b25c-e2ee8d2fac95.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:57:52.191Z.